HD Labs | Tirzepatide 30mg (Not Mixed) | Compound Peptide Vial
Advanced Dual Incretin Receptor Research Compound
HD LABS Tirzepatide 30 is an investigational peptide research compound studied for its dual agonist activity across GIP and GLP-1 receptor pathways, widely referenced in laboratory research exploring metabolic regulation, insulin signalling, and energy homeostasis mechanisms.
Tirzepatide is commonly investigated in scientific models focused on glucose metabolism, appetite regulation pathways, and multi-receptor endocrine signalling within controlled experimental environments.
Developed as a 30mg compound peptide vial (Not Mixed), this formulation is supplied in an unmixed format intended for laboratory preparation and controlled research applications where dual incretin receptor activity and metabolic pathway analysis are of scientific interest.
HD LABS Tirzepatide 30mg Compound Peptide Vial (Not Mixed)
• Dual GIP/GLP-1 receptor research compound studied in metabolic signalling models
• Investigated in insulin response and glucose regulation research
• Of interest in appetite control and energy balance pathway studies
• Explored in multi-receptor endocrine signalling research environments
• 30mg unmixed vial format designed for laboratory preparation use
• Supplied in “Not Mixed” form for controlled research handling
• High-purity investigational formulation from HD LABS
• Strictly intended for laboratory research use only
⚖️ DISCLAIMER
This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPHRA) for human or animal use.
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.
Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.
